Therapy-related AML and MDS: Mutational Profiles Should Determine Treatment Approach

The 58^th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in San Diego, CA, on December 3–6, 2016.

On Sunday 4^th December, an educational session was held between 7:30am and 9:00am in the “AML According to WHO: Newer Approaches to Therapy” category. This session was moderated by Jessica K. Altman, MD, of the Northwestern University.

In this session, Michael Heuser, MD, of the Hannover Medical School, Hannover, Germany, gave a presentation titled “Therapy-Related Myeloid Neoplasms: Does Knowing the Origin Help to Guide Treatment?”

In a video interview published on Cancer Network, Michael Heuser discussed his presentation further. He emphasized the effect of genetic mutations on therapeutic options in therapy-related Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Michael Heuser concluded by stating that patients with therapy-related AML and MDS have a worse prognosis and should be treated according to their genetic risk group.